10:05 AM EST - Numinus Wellness Inc. : Has received new amendments under Canada's Controlled Drugs and Substances Act that enhance the Company's ability to lead psychedelics research and support the global psychedelics sector. Numinus Bioscience, which operates a state-of-the-art research lab in British Columbia, Canada , recently received amendments to its federal licence to allow the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelics including – for the first time – Ketamine and Lysergic acid diethylamide (LSD). The amendment also supports Numinus Bioscience's role in these activities related to Mescaline, N,N-Dimethyltryptamine (DMT), N-Methyl-3,4, methylenedioxyamphetamine (MDMA), Psilocin and Psilocybin. Numinus Wellness Inc.
shares V.NUMI are trading up 3 cents at $1.43.
